Development of Therapeutic Antibodies as Medical Countermeasures to Biological Agents in Defence Research and Development Canada, Suffield Research Centre

PDF

Authors
  1. Hu, W.-G.
  2. Braid, L.
  3. Hayward, S.
  4. Cherwonogrodzky, J.
  5. Nagata, L.
Corporate Authors
Defence Research and Development Canada, Suffield Research Centre, Ralston AB (CAN)
Abstract
Antibodies are naturally produced in the body as highly versatile defence molecules to infectious agents and toxins, and have great potential for countering biological agents not addressed by current medical countermeasures. DRDC, Suffield Research Centre has a significant strength in research and development of therapeutic antibodies against biological agents with a state-of-the-art humanization strategy for converting mouse antibodies to human antibodies for clinical applications. Using this platform, a number of therapeutic antibodies against various biological agents have been developed. The most recently developed therapeutic anti-ricin antibody exhibits the highest efficacy among the reported anti-ricin antibodies. A tiny dose of 5 ƒÊg per mouse of this humanized anti-ricin antibody, when administered to mice 20 hours after an intranasal challenge with 2~LD50 of ricin, was sufficient to res cue all the mice. Unfortunately, therapeutic antibodies are among the most expensive drugs. In order to reduce the cost, plants are being used for the Good Manufacturing Practices (GMP) production of our therapeutic antibodies in preclinical stage, supported by Defense Threat Reduction Agency (DTRA), Canadian Biological Warfare Threat Medical Countermeasure (BWTMCM) Project and Preclinical-Funded Service of American National Institutes of Health (NIH). The plant-derived anti-ricin antibody will be evaluated to ensure it is indistinguishable from its conventional mammalian-derived c
Keywords
biological agents;anti-ricin;anti-VEEV;therapeutic antibodies;medical countermeasures;plant-derived antibodies;antibody transgene delivery;mesenchymal stromal cells
Report Number
DRDC-RDDC-2015-P104 — External Literature
Date of publication
23 Oct 2015
Number of Pages
17
DSTKIM No
CA041328
CANDIS No
802431
Format(s):
Electronic Document(PDF)

Permanent link

Document 1 of 1

Date modified: